Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain AXGN message board posts where the ticker symbol AXGN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest AXGN SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-012519 Size: 5 KB
2018-11-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-012518 Size: 5 KB
2018-11-05
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-18-012372 Size: 3 KB
2018-10-29
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-18-012371 Size: 3 KB
2018-10-29
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-18-012370 Size: 3 KB
2018-10-29
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-18-012369 Size: 3 KB
2018-10-29
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-007981 (34 Act)  Size: 4 MB
2018-10-29 001-36046
181144384
8-K  Documents Current report, items 1.01, 2.02, 2.03, 5.02, and 9.01
Acc-no: 0001558370-18-007978 (34 Act)  Size: 1 MB
2018-10-29 001-36046
181144344
8-K  Documents Current report, item 5.02
Acc-no: 0001558370-18-007795 (34 Act)  Size: 27 KB
2018-10-23 001-36046
181134289
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-012049 Size: 4 KB
2018-10-03
More AXGN SEC Filings


Related news from
Fri, 09 Nov 2018
13:10:00 +0000
New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tue, 06 Nov 2018
12:00:00 +0000
AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018
AxoGen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will host its Third Annual Analyst and Investor Day on Monday, November 19, 2018 in New York City from 11:30 a.m. – 3:30 p.m. ET. AxoGen executives and surgeon thought leaders will discuss the company’s comprehensive platform for peripheral nerve repair and the emerging nerve repair market. AxoGen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
Thu, 01 Nov 2018
15:06:28 +0000
Edited Transcript of AXGN earnings conference call or presentation 29-Oct-18 8:30pm GMT
Q3 2018 AxoGen Inc Earnings Call
Tue, 30 Oct 2018
06:19:39 +0000
AxoGen (AXGN) Q3 2018 Earnings Conference Call Transcript
AXGN earnings call for the period ending September 30, 2018.
Mon, 29 Oct 2018
22:10:10 +0000
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Mon, 29 Oct 2018
21:04:27 +0000
AxoGen: 3Q Earnings Snapshot
On a per-share basis, the Alachua, Florida-based company said it had a loss of 11 cents. Losses, adjusted for stock option expense, came to 5 cents per share. The results met Wall Street expectations. ...
Mon, 29 Oct 2018
20:01:00 +0000
AxoGen, Inc. Reports 2018 Third Quarter Financial Results
Q3 Revenue of $22.7 million, representing 41% growth over prior year; Management reiterates full year 2018 guidance and introduces 2019 guidance ALACHUA, Fla., Oct..
Mon, 29 Oct 2018
20:00:00 +0000
Avance® Nerve Graft Receives Regenerative Medicine Advanced Therapy (RMAT) Designation
AxoGen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today reported that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Avance® Nerve Graft. The RMAT designation, under the 21st Century Cures Act, aims to streamline development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions.
Mon, 29 Oct 2018
18:48:29 +0000
Medical technology company to create 200 new jobs in Dayton area
A medical technology company is planning to create 200 new jobs in the Dayton area as it prepares to open a new facility.
Wed, 17 Oct 2018
11:55:00 +0000
Report: Exploring Fundamental Drivers Behind Infinity Pharmaceuticals, AxoGen, MUELLER WATER PRODUCTS, MYR Group, RealNetworks, and Odonate Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tue, 16 Oct 2018
11:00:00 +0000
AxoGen, Inc. to Report Third Quarter 2018 Financial Results and Host Conference Call on October 29, 2018
AxoGen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will report third quarter 2018 financial results on Monday, October 29, 2018 after the market closes. AxoGen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET to discuss the financial results and provide a corporate update. AxoGen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
Tue, 25 Sep 2018
09:05:09 +0000
Bull of the Day: Penumbra (PEN)
Bull of the Day: Penumbra (PEN)
Mon, 24 Sep 2018
11:00:00 +0000
AxoGen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
AxoGen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, chief executive officer, and president, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City. AxoGen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
Fri, 07 Sep 2018
11:00:00 +0000
AxoGen to Participate at 73rd Annual American Society for Surgery of the Hand Meeting
ALACHUA, Fla., Sept. 07, 2018 (GLOBE NEWSWIRE) --  AxoGen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in the 73rd Annual Meeting of the American Society for Surgery of the Hand (ASSH). The meeting, scheduled for September 13-15 at the Hynes Convention Center in Boston, is the largest international gathering of hand surgeons and features scientific sessions, training opportunities, poster presentations, and exhibits. AxoGen is a premier partner for the meeting and will host a lunch symposium and panel discussion on Friday, September 14 at 12:15 p.m. The symposium, Practical Pearls for Adopting an Evidence-Based Nerve Repair Algorithm, will include a discussion with three of the country’s leading nerve surgeons.
Tue, 04 Sep 2018
11:00:00 +0000
AxoGen, Inc. Appoints Angelo G. Scopelianos, Ph.D. as Vice President, Research and Development
ALACHUA, Fla., Sept. 04, 2018-- AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced the appointment ...
Tue, 28 Aug 2018
11:00:00 +0000
AxoGen, Inc. to Present at the Morgan Stanley Global Healthcare Conference
ALACHUA, Fla., Aug. 28, 2018-- AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Peter J. Mariani, chief financial officer, ...
Mon, 20 Aug 2018
11:30:00 +0000
Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blucora, ...
Fri, 10 Aug 2018
17:40:14 +0000
Edited Transcript of AXGN earnings conference call or presentation 1-Aug-18 8:30pm GMT
Q2 2018 AxoGen Inc Earnings Call
Thu, 02 Aug 2018
19:44:00 +0000
Here's Why AxoGen, Inc. Fell as Much as 18.6% Today
The healthcare company reported second-quarter 2018 earnings.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is a great group of very smart, sophisticated investors. We have several professionals on board managing millions of dollars, and "average Joe" investors that beat the pants off of Wall Street professionals year in and year out. ValueForum will expose you to a wealth of ideas and sectors, and keep you ahead of the curve." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards